ERBB2 and renal pelvis/ureter urothelial carcinoma: In urothelial cancer, ERBB2 mutations were predominantly localized to the extracellular domain (52.4%, 144/275) with mutations involving the oncogenic S310F/Y allele most common (6.8% of bladder and 3.1% of UTUC tumors harbored a S310F/Y mutation, Fig. 1B, and Supplementary Fig. 1C)22,23.